---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-284839"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2021-09-28T23:59:59+00:00"
generated_at: "2026-06-29T00:55:32.702564+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Altimmune Phase 1 pemvidutide shows 10.3% mean weight loss at 1.8 mg; NASH IND cleared

## Summary
- Mean weight loss of 10.3% at 1.8 mg dose vs. 1.6% placebo; 100% of subjects lost ≥5%.
- No discontinuations due to adverse events; side effects mild-to-moderate, no dose titration needed.
- FDA cleared IND for NASH; 12-week NAFLD liver fat trial to start soon.
- Phase 2 obesity trial (48-week) planned for H1 2022; diabetes trial expected Q4 2021.
- Favorable trends in blood pressure, lipids, HOMA-IR; ketone bodies rise supports glucagon mechanism.

## SEC filing metadata
- accession: 0001193125-21-284839
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2021-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000119312521284839/0001193125-21-284839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000119312521284839/d200964d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-284839
- JSON: https://secwatch.observer/filing/0001193125-21-284839.json
- Plain text: https://secwatch.observer/filing/0001193125-21-284839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.